Autor: "Ludwig JA" - OpacWWW

Skocz do pozycji: 41.

Tytuł:: Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.
Autorzy:: Wang Z; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Shi N; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Subbiah V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Araujo DM; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Patel SR; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ludwig JA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ramondetta LM; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Levenback CF; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ramirez PT; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hong D; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Karp DD; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2016 Dec; Vol. 5 (12), pp. 3437-3444. Date of Electronic Publication: 2016 Nov 23.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Leiomyosarcoma/*mortality
Leiomyosarcoma/*pathology
Academic Medical Centers ; Adult ; Aged ; Clinical Trials as Topic ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Leiomyosarcoma/complications ; Leiomyosarcoma/drug therapy ; Male ; Middle Aged ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Neoplasm Staging ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Survival Analysis ; Texas ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 42.

Tytuł:: Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.
Autorzy:: Subbiah V; Department of Investigational Cancer Therapeutics (A Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas, USA.; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas, USA.
Hess KR; Division of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas, USA.
Khawaja MR; Department of Investigational Cancer Therapeutics (A Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas, USA.
Wagner MJ; Department of Investigational Cancer Therapeutics (A Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas, USA.
Tang C; Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas, USA.
Naing A; Department of Investigational Cancer Therapeutics (A Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas, USA.
Fu S; Department of Investigational Cancer Therapeutics (A Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas, USA.
Janku F; Department of Investigational Cancer Therapeutics (A Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas, USA.
Piha-Paul S; Department of Investigational Cancer Therapeutics (A Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas, USA.
Tsimberidou AM; Department of Investigational Cancer Therapeutics (A Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas, USA.
Herzog CE; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas, USA.
Ludwig JA; Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas.
Patel S; Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas.
Ravi V; Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas.
Benjamin RS; Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas.
Meric-Bernstam F; Department of Investigational Cancer Therapeutics (A Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas, USA.
Hong DS; Department of Investigational Cancer Therapeutics (A Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas, USA.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2016 Oct 17; Vol. 6, pp. 35448. Date of Electronic Publication: 2016 Oct 17.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Molecular Targeted Therapy*/methods
Sarcoma/*drug therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biomarkers ; Clinical Trials, Phase I as Topic ; Disease Progression ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Retreatment ; Sarcoma/diagnosis ; Sarcoma/mortality ; Survival Analysis ; Treatment Outcome ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 43.

Tytuł:: Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors.
Autorzy:: Jiang Y; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Ludwig JA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Benjamin RS; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Brown RE; From the Department of Pathology, UT Health-Department of Pathology and Laboratory medicine, Houston, Texas, United States of America.
Anderson P; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Pediatric Hematology/Oncology/BMT, Levine Children's Hospital/Levine Cancer Institute, Charlotte, North Carolina, United States of America.
Kurzrock R; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Center for Personalized Cancer Therapy and Division of Hematology & Oncology, University of California San Diego - Moores Cancer Center, La Jolla, California, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2014 Aug 13; Vol. 9 (8), pp. e93676. Date of Electronic Publication: 2014 Aug 13 (Print Publication: 2014).
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Mutation*
Bone Neoplasms/*genetics
Desmoplastic Small Round Cell Tumor/*genetics
Sarcoma, Ewing/*genetics
Adolescent ; Adult ; Child ; GRB10 Adaptor Protein/genetics ; Humans ; Middle Aged ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins p21(ras) ; Receptor, IGF Type 1/antagonists & inhibitors ; Young Adult ; ras Proteins/genetics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 44.

Tytuł:: Disentangling how landscape spatial and temporal heterogeneity affects Savanna birds.
Autorzy:: Price B; The Swiss Federal Institute for Forest, Snow and Landscape Research WSL, Birmensdorf, Switzerland ; The University of Queensland,Centre for Spatial Environmental Research, School of Geography, Planning and Environmental Management, St Lucia, Australia.
McAlpine CA
Kutt AS
Ward D
Phinn SR
Ludwig JA; Pokaż więcej
Źródło:: PloS one [PLoS One] 2013 Sep 16; Vol. 8 (9), pp. e74333. Date of Electronic Publication: 2013 Sep 16 (Print Publication: 2013).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Birds/*physiology
Animals ; Biodiversity ; Ecosystem ; Population Dynamics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 45.

Tytuł:: Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.
Autorzy:: Ludwig JA; Departments of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. .
Lamhamedi-Cherradi SE
Lee HY
Naing A
Benjamin R; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2011 Jul 26; Vol. 3 (3), pp. 3029-54. Date of Electronic Publication: 2011 Jul 26.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Ludwig JA"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język